Indian Pharma API & CRAMS Sector Reports Significant Q1 FY27 Profit Growth
Indian active pharmaceutical ingredient (API) and contract development and manufacturing services (CRAMS) companies have reported a substantial acceleration in profit growth during the June 2026 quarter (Q1 FY27). A recent analysis by SOIC and StockScans, covering 24 firms in the Pharma-API & CRAMS segment, revealed that median profit after tax (PAT) surged by 47.1% year-on-year, a sharp increase from the 8% growth recorded in March 2026. Median operating profit also rose by 35.6%, while revenue growth stood at 18.8%.
This impressive profitability improvement, which significantly outpaced revenue gains, is primarily driven by several strategic factors. These include the successful commercialization of contract development and manufacturing organization (CDMO) projects, strategic capacity additions, the launch of new products, and enhanced utilization rates across facilities.
CDMO Projects Drive Earnings for Key Players
Contract Development and Manufacturing Organization (CDMO) services are emerging as a critical growth engine for many companies within the sector. This business model allows pharmaceutical firms to outsource drug development and manufacturing, leading to increased revenue streams for specialized API and CRAMS providers.
Morepen Laboratories, for example, commenced commercial dispatches under a multi-year CDMO mandate valued at approximately ₹825 crore in Q1 FY27, with an additional ₹225 crore in supplies anticipated in Q2. The company is also significantly expanding its API capacity, aiming to double it from roughly 500 KL to 1,000 KL.
Similarly, Aarti Pharmalabs is experiencing a growing contribution from its CDMO segment. Its CDMO revenue escalated from ₹32 crore in FY22 to ₹276 crore in FY26, with projections for 40-50% growth in FY27. The company currently manages 37 commercial projects for 22 different customers, underscoring the segment's robust activity.
Capacity Expansion and Product Innovation Fuel Momentum
Beyond CDMO, strategic capacity utilization and product innovation are key themes supporting the sector's growth. Innova Captab's Jammu facility, for instance, generated around ₹300 crore in revenue in FY26 despite only 5-10% utilization. The report suggests this facility could yield ₹1,400 crore or more at full capacity, with fixed-cost absorption boosting profitability as operations scale up.
Concord Biotech is also leveraging a strong pipeline of new products, including oncology, anti-infective, and antifungal treatments. The company secured two USFDA approvals in June 2026 and aims to significantly increase the contribution of its CDMO business, which currently accounts for 1-2% of sales. Furthermore, the report highlights peptides and GLP-1 therapies as burgeoning opportunities, with companies actively investing in manufacturing capacity and developing projects in these advanced therapeutic areas, including semaglutide, which is already contributing to some businesses' growth.
Broader Healthcare Sector Also Sees Growth
While API and CRAMS demonstrated the most pronounced acceleration, other segments within the broader healthcare sector also experienced continued growth. In June 2026, hospitals reported a median revenue growth of approximately 20% and an operating-profit growth of 17%. Diagnostics firms saw similar trends, with median revenue growth around 21% and operating-profit growth of about 27%. However, the data confirms that the API and CRAMS segment led the charge in terms of profit acceleration.